行情

MDGL

MDGL

Madrigal Pharms
NASDAQ

实时行情|Nasdaq Last Sale

99.08
-19.42
-16.39%
盘后: 99.08 0 0.00% 19:59 12/11 EST
开盘
104.63
昨收
118.50
最高
104.63
最低
98.33
成交量
159.95万
成交额
--
52周最高
148.18
52周最低
82.31
市值
15.29亿
市盈率(TTM)
-22.5146
分时
5日
1月
3月
1年
5年

分析师评级

12位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MDGL 新闻

  • Madrigal Pharmaceuticals prices 1.2M-share offering
  • seekingalpha.15小时前
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.18小时前
  • Madrigal Pharmaceuticals Prices 1.2M Share Secondary Offering @$107.85/Share
  • Benzinga.20小时前
  • Madrigal Pharmaceuticals Announces Pricing of Secondary Offering
  • GlobeNewswire.1天前

更多

所属板块

生物技术和医学研究
-0.34%
制药与医学研究
+0.06%

热门股票

名称
价格
涨跌幅

MDGL 简况

Madrigal Pharmaceuticals, Inc., formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company's lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH). Its product pipeline also includes MGL-3745, which is used in the treatment of NASH and FH. MGL-3196 has completed Phase I single and multiple dose trials in healthy volunteers. MGL-3196 is being developed for dyslipidemia/hypercholesterolemia to lower low-density lipoproteins cholesterol, triglyceride levels and lipoprotein(a). MGL-3196 also reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.
展开

Webull提供Madrigal Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。